SB 203580

Drug Profile

SB 203580

Alternative Names: RWJ 64809; SB203580

Latest Information Update: 28 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; University of Cambridge
  • Class Anti-inflammatories; Antirheumatics; Imidazoles; Pyridines
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Postmenopausal osteoporosis; Rheumatoid arthritis; Septic shock

Most Recent Events

  • 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 07 Jan 2000 A preclinical study has been added to the Musculoskeletal pharmacodynamics section
  • 14 Sep 1999 Preclinical development for Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top